Vetter to expand its secondary packaging service capacity to meet rising demands
![](/46/pdcnewsitem/04/88/89/image_large.jpg)
The Vetter VSP facility in Ravensburg is being expanded to include state-of-the-art packaging and assembly equipment to meet the growing need for complex secondary packaging services.
Investment will contribute to a one-stop solution approach for customers.
Vetter has announced a major expansion of its secondary packaging capacities as a response to rising customer needs and market demands for complex packaging solutions. The need for expansion is also a result of Vetter’s continuous growth in new filling lines and new lyophilizers, which is driving the need for increased downstream secondary packaging capacity. The project, already underway, is occurring within the second floor of Vetter’s existing Secondary Packaging (VSP) facility and will result in an increase of approximately 32,000 sq ft of new packaging capacity.
The planned undertaking, which is expected to be completed over the next several years, will include new fully-automated packaging lines, space for manual and semi-automated packaging processes and assembly equipment for a wide variety of formats.
The Vetter serialization and aggregation service, which fulfills current requirements and is prepared for future requirements of regulatory authorities, will also be expanded. A highly flexible, state-of-the-art syringe blister line will include safety device assembly and equipment for packaging Japan quality. The addition of new state-of-the-art assembly machines for pens and autoinjectors will allow Vetter to meet a majority of the growing market need for these systems. Because Vetter suppliers for the platform technologies are market leaders with a strong reputation in the market, a large selection of diverse pen and autoinjector types are offered.
“Often we hear from customers that a high level of expertise in the assembly and packaging of pens, autoinjectors and safety devices is critical for their success,” said Bernd Stauss, Senior Vice President Production/Engineering for Vetter. “Vetter has this experience and can offer a one-stop solution, from development to filling to secondary packaging including serialization of products; a service that is greatly appreciated by our customers.”
The demand for integrated solutions is steadily growing. In the future, the pharmaceutical service provider will continue to expand its offering for one-stop-shop solutions - especially in complex areas such as the secondary packaging of end-user friendly devices which support patient safety, convenience and compliance. As a result, Vetter has an eye on the entire product life cycle of its customers with the usual high quality standards.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance